GNFT - XBiotech Breakthrough And Other News: The Good Bad And Ugly Of Biopharma
XBiotech makes a crucial breakthrough in True Human antibodies Development
XBiotech Inc. (XBIT) reported that it has made an important breakthrough in the development of True Human antibodies, novel inflammation countering mechanism. This new type of antibody seeks to replace previous-generation True Human anti-IL-1? antibody. The company discovered a panel of new anti-IL-1? antibodies from a human donor earlier this year.
XBiotech had sold its earlier-generation antibody in 2019 for $750 million in cash and up to $600 million in milestone payments. The company is working on a replacement for that antibody panel. Sushma Shivaswamy,